Clinical Trial Update: Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis [NA]

View source ↗

Summary

This trial update describes the development of a quantifiable ultrasound biomarker for hepatic steatosis (fatty liver) with ongoing recruitment for MASLD and NA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease
• Non-alcoholic Fatty Liver Disease

Snippet

Sponsor: ContextVision AB | Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease | NA | Status: RECRUITING